Boulet C, Doerig CD, Carvalho TG
Bieden meer vertrouwen voor wetenschappelijk en onderzoeksgebruik
Mah E, Pei R, Guo Y, Ballard KD, Barker T, Rogers VE, et al
Consultings Executive Insights will explore how payers should strategize their approach to glucagon-like peptide-1 agonists (GLP-1s) as they weigh rising consumer demand and increasing pharma supply with recognition of longer-term return on investment (ROI) opportunity
CJC 1295, ipamorelin, and retatrutide are synthetic peptides short chains of amino acids that have attracted growing interest in fitness, weight management, and certain online wellness communities